

Summary Report on Supplemental Testing of Lot FAV 024 of Anthrax Vaccine Adsorbed

1. Lot Identity

Anthrax Vaccine Adsorbed lot number FAV 024 manufactured by BioPort (Michigan Biologic Products Institute), Lansing, Michigan.

2. Testing Dates

Supplemental testing was performed at BioPort beginning on 4 January 1998 and concluding on 14 May 1999. Samples were collected on 4 January 1998. Results were reported by BioPort on 4 June 1999.

3. Standard Operating Procedures (SOPs)

All tests were performed using the most recent version of the applicable BioPort SOPs. Some SOPs were updated after the test plan was written but before the testing began. Changes in the SOPs were technically acceptable, and had no detrimental effect on testing.

4. Testing Summary

The vaccine lot passed all supplemental testing. All testing was performed according to Food and Drug Administration (FDA) guidelines and BioPort SOPs. All results were acceptable, and all associated quality control samples were acceptable. The report issued by BioPort is an accurate reflection of the testing.

Minor deviations from the SOPs occurred during testing. These deviations had no impact on the results.

Mitretek personnel observed all steps of the sampling and testing.